Phase 2Status unknown
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
A Prospective Multicenter Clinical Study to Evaluate The Safety and Efficiency of Human Umbilical Cord Mesenchymal Stem Cell Transfusion in Patients With Decompensated Liver Cirrhosis.
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd. (Industry)
- Enrollment
- 252 planned
- Conditions
- Decompensated Liver Cirrhosis
- Interventions
- UC-MSC
- Ages
- adults, older adults
- Registry
- NCT03529136
Full record on ClinicalTrials.gov
From the registry
Decompensated liver cirrhosis is one of the life-threatening complication of chronic liver disease. Liver transplantation currently is the only effective method that can improve the survival of these patients. However, the severe shortage of donor livers, high cost, and potential serious complications have restricted the availability of liver transplantation.Umbilical cord mesenchymal stem cells (UC-MSC) has been generally shown to be safe and effective for liver diseases in some pre-clinical and clinical studies. This study aim to evaluate the safety and efficiency of human umbilical cord mesenchymal stem cell transfusion in patients with decompensated liver cirrhosis, and explore the best protocol of MSC transfusion.
Primary outcomes
- overall survival
History
Study completion
Primary completion
Started
Registered